This article is more than 5 years old. Information may no longer be current.

VIDEO: Anti-VEGF agents allow broad, effective treatment for ROP, but laser still has a role

ByDarius M. Moshfeghi, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — At the Retina World Congress, Darius M. Moshfeghi, MD, professor and chairman of the retina service at Byers Eye Institute at Stanford University, discusses the advantages of anti-VEGF agents over laser for the treatment of retinopathy of prematurity, but he cautions that it is not a “one-and-done” therapy.